GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arvinas Inc (NAS:ARVN) » Definitions » Piotroski F-Score

Arvinas (Arvinas) Piotroski F-Score : 3 (As of Apr. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Arvinas Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arvinas has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Arvinas's Piotroski F-Score or its related term are showing as below:

ARVN' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 4
Current: 3

During the past 8 years, the highest Piotroski F-Score of Arvinas was 4. The lowest was 3. And the median was 4.


Arvinas Piotroski F-Score Historical Data

The historical data trend for Arvinas's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arvinas Piotroski F-Score Chart

Arvinas Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial 4.00 3.00 4.00 4.00 3.00

Arvinas Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 2.00 2.00 2.00 3.00

Competitive Comparison of Arvinas's Piotroski F-Score

For the Biotechnology subindustry, Arvinas's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arvinas's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arvinas's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Arvinas's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -81.9 + -66.6 + -64 + -154.8 = $-367.30 Mil.
Cash Flow from Operations was -91.2 + -88.7 + -84.8 + -83.1 = $-347.80 Mil.
Revenue was 32.5 + 54.5 + 34.6 + -43.1 = $78.50 Mil.
Gross Profit was 32.5 + 54.5 + 34.6 + -43.1 = $78.50 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(1268.8 + 1175.8 + 1083.5 + 1058.3 + 1304.6) / 5 = $1178.2 Mil.
Total Assets at the begining of this year (Dec22) was $1,268.80 Mil.
Long-Term Debt & Capital Lease Obligation was $1.30 Mil.
Total Current Assets was $1,280.20 Mil.
Total Current Liabilities was $257.10 Mil.
Net Income was -63.4 + -70 + -66.2 + -82.9 = $-282.50 Mil.

Revenue was 26.5 + 33.8 + 33.2 + 37.8 = $131.30 Mil.
Gross Profit was 26.5 + 33.8 + 33.2 + 37.8 = $131.30 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1581.6 + 1488.3 + 1407 + 1334.8 + 1268.8) / 5 = $1416.1 Mil.
Total Assets at the begining of last year (Dec21) was $1,581.60 Mil.
Long-Term Debt & Capital Lease Obligation was $3.70 Mil.
Total Current Assets was $1,240.20 Mil.
Total Current Liabilities was $295.10 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arvinas's current Net Income (TTM) was -367.30. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arvinas's current Cash Flow from Operations (TTM) was -347.80. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-367.3/1268.8
=-0.28948613

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-282.5/1581.6
=-0.17861659

Arvinas's return on assets of this year was -0.28948613. Arvinas's return on assets of last year was -0.17861659. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Arvinas's current Net Income (TTM) was -367.30. Arvinas's current Cash Flow from Operations (TTM) was -347.80. ==> -347.80 > -367.30 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=1.3/1178.2
=0.00110338

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=3.7/1416.1
=0.00261281

Arvinas's gearing of this year was 0.00110338. Arvinas's gearing of last year was 0.00261281. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=1280.2/257.1
=4.97938545

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=1240.2/295.1
=4.20264317

Arvinas's current ratio of this year was 4.97938545. Arvinas's current ratio of last year was 4.20264317. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Arvinas's number of shares in issue this year was 61.2. Arvinas's number of shares in issue last year was 53.5. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=78.5/78.5
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=131.3/131.3
=1

Arvinas's gross margin of this year was 1. Arvinas's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=78.5/1268.8
=0.06186948

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=131.3/1581.6
=0.0830172

Arvinas's asset turnover of this year was 0.06186948. Arvinas's asset turnover of last year was 0.0830172. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arvinas has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Arvinas  (NAS:ARVN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Arvinas Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Arvinas's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Arvinas (Arvinas) Business Description

Traded in Other Exchanges
N/A
Address
395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Executives
Ronald Peck officer: Chief Medical Officer C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sunil Agarwal director 60 LEVERONI COURT, NOVATO CA 94949
Ian Taylor officer: Senior Vice President, Biology C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 0651
John G Houston director, officer: President and CEO C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sean A Cassidy officer: Chief Financial Officer 322 EAST MAIN STREET, BRANFORD CT 06405
Everett Cunningham director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
David K Loomis officer: Chief Accounting Officer C/O 5 SCIENCE PARK, 385 WINCHESTER AVENUE, NEW HAVEN CT 06511
John D Young director C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Liam Ratcliffe director, 10 percent owner C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Timothy M Shannon director C/O CURAGEN CORP, 555LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Bradley Albert Margus director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Kennedy Edward Moore Jr. director C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Wendy L Dixon director
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139